ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer Meeting Abstract
| Authors: | Marth, C.; Vulsteke, C.; Rubio, M. J.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Radoslaw, M.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S. M.; Lee, J.; Pignata, S. |
| Abstract Title: | ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-09-01 |
| Start Page: | mdz250.071 |
| Language: | English |
| ACCESSION: | WOS:000491295503112 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz250.071 |
| Notes: | Meeting Abstract: 1063TiP -- Appears on page v433 of the abstract book -- Source: Wos |
